Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (KZR)
NASDAQ:KZR
Kezar Life Sciences (KZR) Stock Price & Analysis
275 Followers
KZR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.25 - $11.02
Previous Close$2.44
Volume1.17M
Average Volume (3M)1.05M
Market Cap
$176.31M
Enterprise Value-$60.64M
Total Cash (Recent Filing)$257.67M
Total Debt (Recent Filing)$20.72M
Price to Earnings (P/E)-2.3
Beta0.72
Next Earnings
Aug 10, 2023EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding72,407,215
10 Day Avg. Volume760,519
30 Day Avg. Volume1,049,864
Standard Deviation0.26
R-Squared0.00116
Alpha0.00095
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.76
Forecast
1Y Price Target
$16.00Price Target Upside557.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Kezar Life Sciences News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KZR FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was $2.25 and its highest was $11.02 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Currently, no data Available
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is Aug 10, 2023 which is in 61 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on May 11, 2023. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.287 by -$0.023.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Undervalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate is -$0.32.
How many shares outstanding does Kezar Life Sciences Inc have?
Kezar Life Sciences Inc has 72,407,210 shares outstanding.
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.287. Following the earnings report the stock price went up 0.769%.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Among the largest hedge funds holding Kezar Life Sciences Inc’s share is Moore Capital Management LP. It holds Kezar Life Sciences Inc’s shares valued at 266K.
---
Kezar Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (557.08% Upside)
$16.00 (557.08% Upside)
Blogger Sentiment
Neutral
KZR Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.60%
12-Months-Change
Fundamentals
Return on Equity
-30.70%
Trailing 12-Months
Asset Growth
12.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
---
Top 5 ETFs holding KZR
iShares Core S&P Total U.S. Stock Market ETF
$140.33K
iShares NASDAQ US Biotechnology UCITS ETF
$89.68K
iShares Russell 3000 ETF
$40.71K
Invesco Nasdaq Biotechnology ETF
$3.78K
Up to five ETFs with an Outperform Smart Score that hold KZR. The ETFs are listed according to market value of KZR within the ETF
---
---